Nonetheless, regarding the incidence of AKI, no statistical difference was found using the ungraded KDIGO criteria for AKI17 (50.5% in the CFB negative trend group and 40.2% in the CFB positive group), equally finding to PRoVent-COVID-19 study40. This evidence concerns the gene CFB and COVID-19.